HK1252496A1 - 作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物 - Google Patents

作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物

Info

Publication number
HK1252496A1
HK1252496A1 HK18111805.2A HK18111805A HK1252496A1 HK 1252496 A1 HK1252496 A1 HK 1252496A1 HK 18111805 A HK18111805 A HK 18111805A HK 1252496 A1 HK1252496 A1 HK 1252496A1
Authority
HK
Hong Kong
Prior art keywords
mono
viral replication
indole derivatives
substituted indole
replication inhibitors
Prior art date
Application number
HK18111805.2A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of HK1252496A1 publication Critical patent/HK1252496A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18111805.2A 2015-05-08 2018-09-14 作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物 HK1252496A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31

Publications (1)

Publication Number Publication Date
HK1252496A1 true HK1252496A1 (zh) 2019-05-31

Family

ID=56026812

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18111747.3A HK1252446A1 (zh) 2015-05-08 2018-09-13 作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物
HK18111805.2A HK1252496A1 (zh) 2015-05-08 2018-09-14 作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18111747.3A HK1252446A1 (zh) 2015-05-08 2018-09-13 作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物

Country Status (38)

Country Link
US (3) US10696632B2 (zh)
EP (2) EP3294738B1 (zh)
JP (4) JP6752821B2 (zh)
KR (2) KR102610491B1 (zh)
CN (3) CN113045476A (zh)
AU (2) AU2016259677B2 (zh)
BR (1) BR112017023904A2 (zh)
CA (1) CA2981845C (zh)
CL (1) CL2017002817A1 (zh)
CO (1) CO2017012381A2 (zh)
CR (2) CR20200152A (zh)
CY (1) CY1124548T1 (zh)
DK (1) DK3294738T3 (zh)
EA (1) EA034978B1 (zh)
EC (2) ECSP17073878A (zh)
ES (2) ES2877404T3 (zh)
GT (1) GT201700234A (zh)
HK (2) HK1252446A1 (zh)
HR (1) HRP20210675T1 (zh)
HU (1) HUE054724T2 (zh)
IL (2) IL255430B (zh)
JO (2) JOP20160086B1 (zh)
LT (1) LT3294738T (zh)
MD (1) MD3294738T2 (zh)
MX (2) MX2020011156A (zh)
NI (1) NI201700137A (zh)
PE (2) PE20180232A1 (zh)
PH (1) PH12017502000A1 (zh)
PL (1) PL3294738T3 (zh)
RS (1) RS62029B1 (zh)
SG (1) SG10201900315SA (zh)
SI (1) SI3294738T1 (zh)
SV (1) SV2017005557A (zh)
TW (2) TWI744963B (zh)
UA (1) UA121332C2 (zh)
UY (2) UY39706A (zh)
WO (1) WO2016180696A1 (zh)
ZA (1) ZA202002435B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3436436B1 (en) 2016-03-31 2022-05-11 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JP6888021B2 (ja) 2016-03-31 2021-06-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドール誘導体
CR20180494A (es) * 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
CR20190531A (es) * 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EP4058019A1 (en) 2019-11-15 2022-09-21 Janssen Pharmaceuticals, Inc. Treatment and prevention of dengue disease
WO2022094816A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团（天津）股份有限公司 连续化合成取代吲哚-2-羧酸的方法
CN117616010A (zh) 2021-06-29 2024-02-27 杨森制药公司 制备(s)-2-(4-氯-2-甲氧基苯基)-2-((3-甲氧基-5-(甲磺酰基)苯基)氨基)-1-(1h-吲哚-3-基)乙烯酮衍生物的方法
WO2023218285A1 (en) 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830335T2 (de) 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
CA2468202A1 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2293671A4 (en) 2008-06-03 2012-03-21 Siga Technologies Inc SMALL MOLECULAR INHIBITORS FOR TREATING OR PREVENTING DENGUE INFECTIONS
BRPI0917394A2 (pt) * 2008-08-18 2019-09-24 Univ Yale moduladores de mif
EP2331499B1 (en) 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
CN102712632A (zh) 2010-01-15 2012-10-03 吉里德科学公司 黄病毒科病毒的抑制剂
JP2013523657A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのインダゾリル‐ピリミジン
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
CA2949981C (en) 2014-06-04 2023-03-14 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
ES2711117T3 (es) * 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
SI3201176T1 (sl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals, Inc. Mono-ali di-substituirani derivati indola kot inhibitorji replikacije virusa denga
NO2721243T3 (zh) 2014-10-01 2018-10-20
ES2896198T3 (es) 2014-10-10 2022-02-24 Univ Rutgers Cebadores y sondas de reacción en cadena de polimerasa para Mycobacterium tuberculosis
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016296923B2 (en) 2015-07-22 2019-02-21 Board Of Regents, The University Of Texas System Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
RU2761212C2 (ru) 2015-11-03 2021-12-06 Зоэтис Сервисиз Ллс Полимерные композиты, полученные по способу золь-гель, и их применение
JP6888021B2 (ja) 2016-03-31 2021-06-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドール誘導体
CA3019298C (en) 2016-03-31 2023-08-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3436436B1 (en) 2016-03-31 2022-05-11 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
MA43603A1 (fr) 2016-04-01 2019-03-29 Amgen Inc Récepteurs chimériques et leurs procédés d'utilisation
EP3436479A1 (en) 2016-04-01 2019-02-06 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102411744B1 (ko) 2016-04-01 2022-06-21 바스프 에스이 바이시클릭 화합물
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
IL303785A (en) 2016-04-01 2023-08-01 Kite Pharma Inc Chimeric antigen and T cell receptors and methods of use
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Also Published As

Publication number Publication date
HUE054724T2 (hu) 2021-09-28
EA201792429A1 (ru) 2018-02-28
US20180346419A1 (en) 2018-12-06
US20210171462A1 (en) 2021-06-10
IL272814B (en) 2021-02-28
KR20210048578A (ko) 2021-05-03
KR102610493B1 (ko) 2023-12-05
EA034978B1 (ru) 2020-04-14
PH12017502000B1 (en) 2018-03-26
CR20170490A (es) 2018-03-08
JOP20160086B1 (ar) 2021-08-17
GT201700234A (es) 2018-11-26
AU2020273314B2 (en) 2021-10-21
US20200270209A1 (en) 2020-08-27
EP3294738A1 (en) 2018-03-21
JP2021138752A (ja) 2021-09-16
CY1124548T1 (el) 2022-07-22
UA121332C2 (uk) 2020-05-12
IL255430A0 (en) 2017-12-31
HK1252446A1 (zh) 2019-05-24
CN107873022A (zh) 2018-04-03
PL3294738T3 (pl) 2021-12-13
PE20221579A1 (es) 2022-10-06
NZ736934A (en) 2023-11-24
NI201700137A (es) 2019-05-07
UY36674A (es) 2016-11-30
EP3294738B1 (en) 2021-04-07
ZA202002435B (en) 2023-03-29
ECSP17073878A (es) 2018-02-28
TWI744963B (zh) 2021-11-01
CN113045476A (zh) 2021-06-29
MX2017014293A (es) 2018-08-09
EP3896072A1 (en) 2021-10-20
AU2016259677B2 (en) 2020-10-01
CL2017002817A1 (es) 2018-05-11
US11827602B2 (en) 2023-11-28
KR20180002644A (ko) 2018-01-08
US10919854B2 (en) 2021-02-16
CR20200152A (es) 2020-09-08
JP7132399B2 (ja) 2022-09-06
AU2016259677A1 (en) 2017-10-26
CA2981845A1 (en) 2016-11-17
TW202041499A (zh) 2020-11-16
IL255430B (en) 2020-03-31
CN107873022B (zh) 2021-03-12
JP2020125316A (ja) 2020-08-20
JP7451626B2 (ja) 2024-03-18
CA2981845C (en) 2022-03-08
PE20180232A1 (es) 2018-01-31
HRP20210675T1 (hr) 2021-06-25
LT3294738T (lt) 2021-08-25
UY39706A (es) 2022-05-31
IL272814A (en) 2020-04-30
PH12017502000A1 (en) 2018-03-26
JP6898493B2 (ja) 2021-07-07
MX2020011156A (es) 2022-04-21
DK3294738T3 (da) 2021-06-28
CN111303000B (zh) 2023-11-28
SI3294738T1 (sl) 2021-08-31
EP3896072B1 (en) 2022-11-16
WO2016180696A1 (en) 2016-11-17
CO2017012381A2 (es) 2018-03-28
ES2877404T3 (es) 2021-11-16
JP2018515495A (ja) 2018-06-14
SG10201900315SA (en) 2019-02-27
TW201704208A (zh) 2017-02-01
JOP20210109A1 (ar) 2023-01-30
ECSP22023220A (es) 2022-05-31
RS62029B1 (sr) 2021-07-30
BR112017023904A2 (pt) 2018-07-17
JP6752821B2 (ja) 2020-09-09
ES2941674T3 (es) 2023-05-24
KR102610491B1 (ko) 2023-12-06
CN111303000A (zh) 2020-06-19
US10696632B2 (en) 2020-06-30
JP2022166289A (ja) 2022-11-01
MD3294738T2 (ro) 2021-08-31
TWI725969B (zh) 2021-05-01
SV2017005557A (es) 2018-06-26
AU2020273314A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
ZA202002435B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
HRP20190199T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
HK1258320A1 (zh) 作為登革熱病毒複製抑制劑的單取代或二取代吲哚衍生物
HK1257842A1 (zh) 作為登革熱病毒複製抑制劑的單取代的或二取代的吲哚衍生物
HRP20190139T1 (hr) Mono- ili di-supstituirani indoli kao inhibitori replikacije denga virusa
HK1246688A1 (zh) 作為登革熱病毒複製抑制劑的吲哚衍生物
PT3294738T (pt) Derivados mono ou di-substituídos de indol como inibidores da replicação viral da dengue